Rapamycin for Dog Aging & Canine Cognitive Dysfunction: What the TRIAD Trial Actually Shows in 2026
Short answer: Rapamycin is a serious research candidate in canine geroscience, but it has not been proven to reverse dog dementia and it is not FDA-approved for canine cognitive dysfunction (CCD). The Dog Aging Project’s TRIAD trial is testing whether once-weekly rapamycin can extend lifespan and improve healthspan in healthy, middle-aged to senior dogs. Cognition is one of several secondary outcomes; published TRIAD papers do not report a 30% cognitive improvement or a successful CCD treatment result.
What is actually established as of September 20, 2026?
TRIAD target: 580 healthy companion dogs, randomized to rapamycin or placebo.
Design: 12 months of once-weekly treatment followed by 24 months of monitoring.
Primary question: Does rapamycin increase lifespan?
Secondary questions: Does it improve healthspan measures including physical, cardiovascular, neurologic and cognitive function?
CCD treatment claim: Not established. TRIAD is not a trial of dogs diagnosed with dementia.
FDA status: No FDA approval or conditional approval for rapamycin to treat canine CCD was identified in current FDA or Dog Aging Project sources.
Major correction from the previous version: The earlier article stated that TRIAD had shown about 30% cognitive improvement versus placebo and that an FDA conditional-approval package had been submitted in Q4 2025. We could not verify either claim in the published TRIAD literature, current Dog Aging Project materials or FDA sources. Those statements have been removed.
What TRIAD is — and what it is not
The Test of Rapamycin in Aging Dogs (TRIAD) is a prospective, double-masked, randomized, placebo-controlled multicenter trial within the Dog Aging Project. The peer-reviewed design paper published in GeroScience in 2025 describes a planned enrollment of 580 dogs, with 290 assigned to rapamycin and 290 to placebo.
Dogs receive study drug once weekly for 12 months and are then followed for another 24 months. The study’s primary endpoint is lifespan. Healthspan measures — including physical function, frailty, cardiovascular health and neurocognitive function — are secondary outcomes.
This distinction matters: TRIAD was designed to study biological aging in healthy dogs, not to treat established canine dementia. Current clinical-site information lists significant neurologic disease among exclusion criteria. A dog already showing clear CCD signs should therefore be evaluated clinically rather than assuming TRIAD is a treatment-access program.
Where did the “580 dogs” number come from?
It is a target enrollment, not proof that 580 dogs had already completed the study. The 2025 design paper reported that, at the time the manuscript was prepared, 252 dogs had been screened and 158 had been enrolled and randomized. Texas A&M reported 170 enrolled dogs in December 2024 when announcing NIH funding to expand the trial toward 580. Current veterinary trial-site pages continue to describe TRIAD as recruiting.
So the correct wording is: TRIAD is designed for 580 dogs. It should not be described as a completed 580-dog efficacy trial unless the project later publishes data showing that milestone.
What has actually been published about rapamycin in dogs?
| Study | Dogs | What it tested | What it found |
|---|---|---|---|
| Urfer et al., 2017 | 24 healthy middle-aged dogs | 10 weeks of low-dose rapamycin vs placebo; safety and cardiac measures | No significant clinical side effects were detected; several echocardiographic measures suggested favorable cardiac changes. This was not a CCD treatment trial. |
| Barnett et al., 2023 | 17 healthy client-owned dogs | 6 months of low-dose rapamycin vs placebo; safety and cardiac function | Rapamycin was well tolerated, but there were no statistically significant differences in echocardiographic parameters between groups at 6 or 12 months. |
| TRIAD design paper, 2025 | 580 planned | Lifespan primary endpoint; multiple healthspan secondary endpoints | Study design and rationale — not final efficacy results. |
| TRIAD cognition report, 2024 | 35 dogs evaluated at baseline | Baseline CADES and Sustained Gaze assessments | Baseline cognitive data only. The publication explicitly states that the randomized trial is underway; it does not report rapamycin treatment benefit. |
The published evidence therefore supports a much narrower conclusion than the old article: low-dose/intermittent rapamycin has been feasible and reasonably tolerated in small studies of healthy dogs, and TRIAD is testing whether longer-term treatment improves lifespan and healthspan. That is scientifically interesting — but it is not the same as showing that rapamycin reverses CCD.
What about mTOR, autophagy and brain aging?
Rapamycin inhibits mTOR, a central nutrient- and growth-signaling pathway involved in cellular metabolism, protein synthesis and autophagy. In laboratory organisms, mTOR inhibition has produced robust effects on aging biology, including lifespan extension in mice. These mechanistic findings are a major reason rapamycin is being tested in companion dogs.
However, mechanistic plausibility should not be converted into a clinical promise. Statements such as “rapamycin clears existing amyloid in dogs” or “resets the aging brain” go beyond the current canine clinical evidence. TRIAD is specifically designed to determine whether promising biology from model organisms translates into meaningful outcomes in real companion dogs.
Is rapamycin in an FDA approval pathway for dog dementia?
We found no current FDA or Dog Aging Project source documenting FDA approval, conditional approval, or a Q4 2025 conditional-approval application for rapamycin as a canine CCD drug. The peer-reviewed TRIAD design paper describes an academic clinical trial of aging, not a regulatory registration trial for canine dementia.
The previous article also described a specific MUMS conditional-approval route. That was speculative. FDA’s Minor Use and Minor Species framework has defined eligibility requirements, and simply studying an age-related condition in dogs does not mean a project is automatically in a MUMS conditional-approval pathway.
Bottom line: Until an identified drug sponsor and the FDA publicly document a canine indication, submission or approval, owners should treat “FDA rapamycin approval for dog dementia is coming next year” as speculation rather than established regulatory fact.
Can veterinarians prescribe sirolimus to dogs off-label?
Sirolimus is an approved human drug. Veterinarians can sometimes use human-approved drugs extralabel in animals under federal veterinary prescribing rules when the legal and clinical requirements are met. That does not make rapamycin an approved canine anti-aging or dementia therapy, and it does not establish an evidence-based dose for an individual dog with CCD.
Rapamycin affects immune and metabolic pathways and can have clinically important adverse effects and drug interactions. Buying human sirolimus online, splitting tablets based on a research dose or using a compounded product without veterinary oversight is not equivalent to participation in a monitored clinical trial.
What canine cognitive dysfunction actually means in 2026
A major evidence update arrived after the original article was written. The international Canine Cognitive Dysfunction Syndrome Working Group published the first practical diagnosis-and-monitoring guideline in late 2025, with the print version appearing in JAVMA in April 2026.
The guideline defines CCDS as a chronic, progressive, age-associated neurodegenerative syndrome in which cognitive and behavioral changes affect daily life. It expands the familiar mnemonic to DISHAA:
D — Disorientation
Getting lost in familiar spaces, staring, difficulty navigating doors or corners.
I — Social interaction
Changes in greeting, attention-seeking, avoidance or relationships with people and other animals.
S — Sleep disruption
Night waking, pacing, vocalization or a changed sleep–wake rhythm.
H — House soiling
Loss of previously learned elimination habits after medical causes are assessed.
A — Activity, learning & memory
Changed activity, repetitive behavior, difficulty with learned tasks or memory.
A — Anxiety
New or worsening anxiety, restlessness or distress that accompanies cognitive decline.
The working group proposes mild, moderate and severe stages. Importantly, CCD is not diagnosed from one odd behavior or an online checklist alone. Level 1 diagnosis requires a progressive history plus evaluation for alternative explanations through physical, orthopedic and neurologic examination and laboratory testing. Level 2 adds brain MRI evidence of cortical atrophy with appropriate CSF findings.
Sudden confusion is not typical CCD
Seek prompt veterinary care for sudden or rapidly worsening disorientation. CCD is typically chronic and progressive. Acute confusion, circling, collapse, new seizures, severe imbalance, head tilt, sudden blindness, toxin exposure or abrupt behavior change can indicate other neurologic or systemic disease and should not be written off as “dog dementia.”
Conditions that can mimic or worsen cognitive signs include pain, hearing or vision loss, endocrine and metabolic disease, urinary problems, medication effects, intracranial disease and sleep disorders. Treating those problems can sometimes produce a large improvement even when a dog also has underlying CCD.
What treatments are evidence-based today?
1. Selegiline
Selegiline hydrochloride (Anipryl) remains the only drug specifically FDA-labeled for control of clinical signs associated with canine Cognitive Dysfunction Syndrome in the United States. AAHA notes that response is variable and that important interactions exist with several antidepressant and other drugs, so it should be prescribed and monitored by a veterinarian.
2. Therapeutic diets and nutritional strategies
AAHA and the Merck Veterinary Manual describe evidence for some diets enriched with medium-chain triglycerides, antioxidants and other nutrients designed to support the aging brain. Evidence for individual supplements varies substantially, and commercial marketing claims are often stronger than the clinical data.
3. Environmental enrichment and routine
Predictable routines, appropriate physical activity, safe cognitive enrichment, accessible food/water stations, night lighting, non-slip flooring and management of anxiety can meaningfully improve quality of life. Enrichment should be adapted to the dog’s mobility, vision, hearing and frustration tolerance rather than made progressively more difficult.
4. Treat concurrent disease
Pain, osteoarthritis, sensory loss, urinary disease, endocrine disorders and sleep problems can magnify apparent cognitive decline. A multimodal plan often helps more than focusing on one “brain supplement.”
About supplements: Some products containing SAMe, phosphatidylserine, antioxidants or related compounds have supportive studies, while evidence for other popular products is limited or inconsistent. “Natural” does not mean interaction-free — tell your veterinarian every supplement and medication your dog receives.
Should a dog with CCD join TRIAD?
TRIAD should not be presented as a dementia-treatment enrollment route. Current trial-site criteria describe participants as apparently healthy dogs at least 7 years old and at least 44 lb, and list significant neurologic disease among exclusions. The project determines final eligibility.
If your dog is cognitively normal and otherwise healthy, a participating TRIAD site may still be recruiting suitable dogs for the aging study. If your dog already has suspected CCD, the more relevant first step is a veterinary cognitive workup and discussion of current management options or CCD-specific research studies.
What owners can do this week
- Record short videos of nighttime pacing, getting stuck, staring, house-soiling patterns or other concerning behavior.
- Write down when the signs began and whether progression has been gradual or sudden.
- Ask for a senior examination that considers pain, vision, hearing, neurologic disease and systemic illness — not just “normal aging.”
- Use a validated caregiver questionnaire such as CADES or another tool recommended by your veterinarian to establish a baseline.
- Review all medications and supplements for interactions before starting selegiline or any new product.
- Make the home easier to navigate: stable furniture placement, non-slip routes, night lights and easy access to water and outdoor elimination.
- Discuss quality of life openly as disease progresses; severe CCD can affect sleep, anxiety, feeding, toileting and the human–animal bond.
Frequently Asked Questions
Did TRIAD show a 30% improvement in dog cognition?
No peer-reviewed TRIAD publication located for this update reports that result. The 2024 cognition publication contains baseline data from dogs being assessed for enrollment and states that the randomized trial is underway. It does not compare treated dogs with placebo.
Is rapamycin expected to reverse canine dementia?
That has not been demonstrated. Rapamycin has strong geroscience rationale and TRIAD includes neurocognitive outcomes, but no published canine clinical trial has established reversal of CCD.
Is TRIAD testing dogs that already have CCD?
No. TRIAD studies healthy aging and lifespan in apparently healthy older dogs. Current site criteria exclude significant neurologic disease. Cognition is measured as a secondary aging outcome rather than treating a cohort diagnosed with dementia.
Has the FDA received a conditional-approval application for rapamycin in CCD?
We could not verify such a submission in FDA or Dog Aging Project sources as of September 20, 2026. The earlier Patify article’s Q4 2025 submission claim has therefore been removed.
Can my vet prescribe rapamycin anyway?
Veterinarians can sometimes prescribe approved human drugs extralabel when legal and clinical requirements are satisfied. Whether rapamycin is appropriate for an individual dog is a separate medical judgment. There is no FDA-approved canine aging or CCD indication, and owners should not copy a research protocol without veterinary supervision.
What is the current approved drug for canine cognitive dysfunction?
Selegiline (Anipryl) is FDA-labeled for control of clinical signs associated with canine Cognitive Dysfunction Syndrome. It is not appropriate for every dog and has important medication interactions, so a veterinarian should supervise treatment.
Is CCD the same as Alzheimer’s disease?
They have important clinical and neuropathologic parallels, which makes dogs valuable for comparative aging research, but they are not identical diseases. Current veterinary guidelines define CCDS on its own clinical criteria rather than diagnosing dogs with human Alzheimer’s disease.
Sources checked September 20, 2026
- Coleman et al., GeroScience (2025) — TRIAD study design and rationale.
- Dog Aging Project (2024) — baseline canine cognition assessments in dogs evaluated for TRIAD.
- Texas A&M VMBS — NIH-funded expansion of TRIAD toward 580 dogs.
- Tufts — current TRIAD recruiting page and eligibility/exclusion criteria.
- Urfer et al., GeroScience (2017) — 10-week rapamycin trial in 24 healthy middle-aged dogs.
- Barnett et al., Frontiers in Veterinary Science (2023) — 6-month low-dose rapamycin trial in 17 healthy dogs.
- Canine Cognitive Dysfunction Syndrome Working Group guideline — published online 2025, JAVMA April 2026.
- AAHA Senior Care Guidelines — cognitive dysfunction diagnosis and management.
- Merck Veterinary Manual — pharmacologic, diet and supplement options for CDS.
- FDA NADA 141-080 — Anipryl/selegiline label for canine Cognitive Dysfunction Syndrome.
Educational information only. Rapamycin is not FDA-approved for canine aging or cognitive dysfunction. New or worsening cognitive/neurologic signs require individual veterinary evaluation.
Cover photo: Lübna Abdullah / Pexels, senior dog resting at home. Pexels marks the image free to use.
